Literature DB >> 7589138

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors.

M C Feltkamp1, G R Vreugdenhil, M P Vierboom, E Ras, S H van der Burg, J ter Schegget, C J Melief, W M Kast.   

Abstract

Previously, we have shown that immunization with human papillomavirus (HPV) type 16-derived cytotoxic T lymphocyte (CTL) epitope E7 49-57 (RAHYNIVTF) renders C57BL/6 mice insensitive to tumors formed by HPV16-transformed cells. In this study, we provide evidence that E7 49-57 is expressed as a subdominant CTL epitope on HPV16-transformed C57BL/6 cells. Using acid peptide elution, it is shown that HPV16-transformed cells express another CTL epitope, besides E7 49-57, which appears to be dominant. We demonstrate that a CTL line raised against the subdominant CTL epitope, offered as synthetic peptide E7 49-57, eradicates established HPV16-induced tumors in mice. Our data show that synthetic peptide-induced CTL can be applied successfully in vivo against (virus-induced) tumor, and emphasize that subdominant CTL epitopes are useful targets for immunotherapy. Furthermore, it is illustrated for the first time that HPV16-specific CTL interfere directly with HPV16-induced tumors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7589138     DOI: 10.1002/eji.1830250935

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  38 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.

Authors:  C Perreault; J Jutras; D C Roy; J G Filep; S Brochu
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

3.  Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses.

Authors:  Andrew W Woodham; Ross W Cheloha; Jingjing Ling; Mohammad Rashidian; Stephen C Kolifrath; Maia Mesyngier; Joao N Duarte; Justin M Bader; Joseph G Skeate; Diane M Da Silva; W Martin Kast; Hidde L Ploegh
Journal:  Cancer Immunol Res       Date:  2018-05-23       Impact factor: 11.151

Review 4.  Immunotherapy II: Antigens, receptors and costimulation.

Authors:  P F Searle; L S Young
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

Review 5.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

6.  Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model.

Authors:  H L Greenstone; J D Nieland; K E de Visser; M L De Bruijn; R Kirnbauer; R B Roden; D R Lowy; W M Kast; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

7.  Macrophages kill human papillomavirus type 16 E6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms.

Authors:  John M Routes; Kristin Morris; Misoo C Ellison; Sharon Ryan
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma.

Authors:  Qinghua Feng; Huafeng Wei; Janice Morihara; Joshua Stern; Mujun Yu; Nancy Kiviat; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  Gynecol Oncol       Date:  2012-07-22       Impact factor: 5.482

9.  Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Authors:  T D Schell; L M Mylin; I Georgoff; A K Teresky; A J Levine; S S Tevethia
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 10.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.